Skip to main content

Main menu

  • Pipeline
    • Clinical
    • Discovery
    • Compounds
    • Regimens
    • Drug Targets
    • Developers
    • Trial Sites
    • Trials
  • News
  • Meetings
  • Members
    • Our Members
    • Core Group
  • About
  • Join Us

Regimens

Regimen Developer(s)
2HRZE + experimental drugs
2HRZE 2HR
BEAT-TB USAID
Bedaquiline - Delamanid with MBT for MDR
Bedaquiline - Linezolid - Levofloxacin with OBR
Bedaquiline - Pretomanid - Linezolid TB Alliance
Bedaquiline - Pretomanid - Linezolid - Moxifloxacin Médecins Sans Frontières
Bedaquiline, Pretomanid, Moxifloxacin, Pyrazinamide TB Alliance
Bedaquiline-Moxifloxacin-Linezolid-Pyrazinamide
CC-11050, Auranofin, Everolimus, Vitamin D3 plus Rifabutin-modified TB Therapy The Aurum Institute NPC, Medicines Development for Global Health
Delamanid with OBR Otsuka Pharmaceutical Development & Commercialization, Inc.
Delamanid, Bedaquiline, OPC-167832 Otsuka Pharmaceutical Development & Commercialization, Inc.
Delpazolid, Bedaquiline, Delamanid, & Moxifloxacin PanACEA
INH, RIF, PZA, MOX
Pravastatin, Rifafour, & Vitamin B6
Pretomanid - Moxifloxacin - Pyrazinamide Regimen TB Alliance
Sutezolid, Bedaquiline, Delamanid, & Moxifloxacin PanACEA
  Would you like to receive updates from the WGND? Join our mailing list:
Interests

About Us

Part of Stop TB Partnership, we are a network of committed individuals devoted to accelerating the development of effective, affordable new therapies for TB.

Visit the Stop TB Partnership
Read about The Global Plan to End TB

Navigate

  • Clinical Pipeline
  • Discovery
  • Developers
  • Trials
  • Trial Sites
  • News
  • Meetings
  • Core Group
  • Members
  • About

Contact

The Working Group for New TB Drugs

40 Wall St, Fl 24th
New York, NY

Contact Us

Follow Us

©2016 Working Group on New TB Drugs. All Rights Reserved. Terms of Reference Site by Darby Communications